Very excited to see the gene therapy flood gates opening; this is now the 2nd therapy approved by the FDA, and many more are on the way. https://www.statnews.com/2019/05/24/hold-novartis-zolgensma-approval/ …
On a 30 to 70 year horizon, the gene therapy market feels fairly ephemeral. Germline edits and IVF sequencing will be drastically more cost-effective as primary treatment. As our genome understanding increases, the gene therapy market will ultimately peak and then rapidly decline
Societal pressure & norm will ultimately push towards germline edits. But there's other factors: fertility globally is plummeting, and we may have no choice. "[Concentration] declined more than 50% from 1973 to 2011... total counts were down by almost 60%" https://www.theatlantic.com/family/archive/2018/10/sperm-counts-continue-to-fall/572794/ …
You can follow @_DanielSinclair.
Tip: mention @threader_app on a Twitter thread with the keyword “compile” to get a link to it.
Enjoy Threader? Sign up.
Since you’re here...
... we’re asking visitors like you to make a contribution to support this independent project. In these uncertain times, access to information is vital. Threader gets 1,000,000+ visits a month and our iOS Twitter client was featured as an App of the Day by Apple. Your financial support will help two developers to keep working on this app. Everyone’s contribution, big or small, is so valuable. Support Threader by becoming premium or by donating on PayPal. Thank you.